Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ISDA highlights failures in antibiotic development pipeline

ISDA highlights failures in antibiotic development pipeline

18th April 2013

Not enough is being done to develop new antibiotics, despite the looming threat posed by deadly drug-resistant bacterial infections, according to the Infectious Diseases Society of America (ISDA).

The organisation has expressed concern that the 2010 target set by its 10 x '20 Initiative – which challenged the industry to get at least ten new systemic antibiotics approved by the US Food and Drug Administration (FDA) by 2020 – is nowhere near to being met.

Indeed, only one product – approved over two years ago – has fulfilled the criteria thus far, with relatively little investment having been allocated by global healthcare companies to tackling this challenge.

The IDSA warned that the creation of new drugs is not keeping pace with superbugs' ability to develop resistance to them, meaning patients are at an ever-growing risk of succumbing to deadly infections during routine care.

IDSA president Dr David Relman said: "Simply put, the antibiotic pipeline is on life support and novel solutions are required to resuscitate it – now."

According to the World Health Organization, antimicrobial resistance is a matter of global importance, with around 440 000 new cases of multidrug-resistant tuberculosis emerging annually.ADNFCR-8000103-ID-801573642-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.